SUPPORT AGREEMENTSupport Agreement • June 15th, 2016 • Carbylan Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SUPPORT AGREEMENT (this “Agreement”), dated as of June 15, 2016, is by and among KalVista Pharmaceuticals Ltd., a private company limited by shares incorporated and registered in England and Wales with number 07543947 and whose registered address is at Building 227 Tetricus Science Park, Porton Down, Salisbury, Wiltshire, SP4 0JQ (the “Company”), and the equityholders of Carbylan Therapeutics, Inc., a Delaware corporation (“Carnivale”), set forth on Schedule A hereto (each, an “Equityholder” and collectively, the “Equityholders”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 15th, 2016 • Carbylan Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 15, 2016 (the “Effective Date”), is made by and among Carbylan Therapeutics, Inc., a Delaware corporation (“Carnivale”) and the Sellers (as defined below). This Agreement is made pursuant to the Share Purchase Agreement (as defined below) and shall be effective as of the Closing (as defined in the Share Purchase Agreement). Capitalized terms used herein have the respective meanings ascribed thereto in the Share Purchase Agreement unless otherwise defined herein.
Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement —Transaction forms combined NASDAQ-listed biopharmaceutical company, focused on the discovery, development and commercialization of plasma kallikrein...Share Purchase Agreement • June 15th, 2016 • Carbylan Therapeutics, Inc. • Pharmaceutical preparations
Palo Alto, California, USA and Salisbury, UK, June 15, 2016— Carbylan Therapeutics, Inc. (Nasdaq: CBYL) and KalVista Pharmaceuticals Ltd., a privately-held biopharmaceutical company, announced today that they, together with the shareholders of KalVista, have entered into a definitive share purchase agreement pursuant to which the shareholders of KalVista will become the majority owners of Carbylan. If approved, Carbylan will be renamed KalVista Pharmaceuticals, Inc.
